• Annual Revenue Increase: Outset Medical Inc (NASDAQ:OM) reported a 13% year-over-year increase in annual revenue to $130.4 million.

• Gross Margin Improvement: Gross margin improved significantly in Q4, reaching 25.3% compared to 16.5% in the same quarter of the previous year.

• Net Loss Reduction: The company reduced its net loss to ($38.6) million in Q4, compared to ($41.4) million in Q4 of the previous year.

• Recurring Revenue Growth: Recurring revenue from Tablo consumables and services exceeded 50% of total revenue in 2023.

• Installed Base Expansion: The Tablo installed base grew by 34% to 5,350 consoles by the end of 2023.

• 2024 Financial Guidance: Outset Medical reaffirmed its 2024 revenue guidance of $145 million to $153 million, with non-GAAP gross margin in the low-30% range.

• Warning! GuruFocus has detected 3 Warning Signs with OM.

On February 21, 2024, Outset Medical Inc (NASDAQ:OM) released its 8-K filing, detailing the financial results for the fourth quarter and full year ended December 31, 2023. The company, known for its innovative Tablo Hemodialysis System designed to simplify and reduce the cost of dialysis, has shown a mixed financial performance with revenue growth and margin expansion, despite a quarterly revenue decrease and a net loss.

Outset Medical Inc (NASDAQ:OM) reported a 13% increase in annual revenue, reaching $130.4 million in 2023, up from $115.4 million in 2022. The fourth quarter, however, saw a slight decrease in net revenue to $30.5 million, a 4.7% drop compared to the same period in the previous year. The company's gross margin saw a substantial increase in the fourth quarter, reaching 25.3%, a significant improvement from the 16.5% reported in the fourth quarter of 2022.

Despite the revenue dip in Q4, the company's focus on recurring revenue streams paid off, with over 50% of the total revenue in 2023 coming from Tablo consumables and services. The installed base of Tablo consoles grew to 5,350 units, indicating a solid expansion in both acute and home care settings.

Operating expenses remained flat year-over-year at $45.1 million for the quarter, with research and development (R&D) expenses slightly increasing. The net loss for Q4 improved to ($38.6) million, or ($0.77) per share, from a net loss of ($41.4) million, or ($0.86) per share, in the same period of the previous year.

Outset Medical Inc (NASDAQ:OM) ended the year with a strong balance sheet, with total cash, cash equivalents, and short-term investments of $206.7 million as of December 31, 2023, although this was down from $290.8 million at the end of 2022.